BioSpace

Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

FDA advisory committee meetings are dominating the biopharma landscape, with the agency challenging the trial data for Capricor’s Duchenne muscular dystrophy therapy and questioning the sufficiency of Replimune’s single-arm study for melanoma. Meanwhile, the second-quarter earnings season is underway, highlighted by GS...

Nordic biotech’s next act: From fragmentation to global force

The Nordic biotech landscape reveals a significant divergence between Denmark’s thriving ecosystem and the structural hurdles facing Sweden, Norway, and Finland. Denmark’s success stems from a unique foundation-led model, exemplified by the Novo Nordisk Foundation and the BioInnovation Institute, which provides long-te...

Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

The biopharma industry enters a busy second-quarter earnings season, with major players like AbbVie, Amgen, and Eli Lilly under scrutiny for their recent acquisitions and product launches. Eli Lilly’s multi-billion dollar investment in Atai Life Sciences signals significant validation for the psychedelic medicine secto...

The future of pain relief: Exploring opioid alternatives

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

The biotech industry is experiencing significant shifts following data readouts from the Alzheimer’s Association International Conference and recent clinical trial results. Biogen’s anti-tau therapy, daranirsen, demonstrated potential in slowing Alzheimer’s progression, while the FDA’s approval of a subcutaneous, at-ho...

Bonus: Q2 2026 Job Market Update

From sequence to scale: Gene editing’s new era in biologics manufacturing

Cell line development serves as the foundational decision in biologics manufacturing, dictating the long-term efficiency and cost-effectiveness of drug production. CHO (Chinese Hamster Ovary) cells remain the industry standard due to their robust growth, regulatory acceptance, and human-like glycosylation patterns. Mod...

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

The biopharma industry experienced significant activity in the first half of 2024, highlighted by Vertex’s $10 billion acquisition of Cryonetics Pharmaceuticals, a major move in the endocrinology space. M&A activity remains robust, with companies like Novartis, Gilead, and GSK actively pursuing deals, though Eli Lilly ...

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

The Golden Triangle and the gaps: Rethinking UK biotech

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

Biopharma M&A activity remains robust, highlighted by AbbVie’s $10.9 billion acquisition of Apogee Therapeutics to bolster its immunology pipeline and address patent cliffs. Regulatory landscapes are shifting, with the FDA reversing previous stances on gene therapies from uniQure and REGENXBIO, signaling a potential mo...

From fragile skin to living medicine: Lessons from RDEB

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Portugal, Spain and the new biotech frontier

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Rethinking hair loss treatment

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

France’s biotech ecosystem: science, capital and scale

Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds

Inside Germany’s biotech capital infrastructure and innovation engine